InflaRx Q2 2026 earnings: Lower costs narrow the operating loss

InflaRx (Nasdaq: IFRX) reported Q2 2026 revenue of €0, down from €39,432 a year earlier, while its basic and diluted loss per share narrowed to €0.09 from €0.21. The operating loss declined to €7.1 million as research, administrative and sales expenses fell, although warrant-related financial effects limited the improvement in net loss. A May equity offering raised liquidity to €158.4 million in cash, cash equivalents and marketable securities at June 30.

Core financial results

InflaRx had neither revenue nor cost of sales during the three months ended June 30, 2026. By comparison, Q2 2025 included €39,432 of revenue and €2.4 million of cost of sales, resulting in a €2.4 million gross loss.

Operating expenses also declined. R&D expense fell by approximately 34%, G&A expense decreased by about 22%, and sales and marketing expense dropped to €30,175 from €1.0 million. For the first six months of 2026, management attributed the lower R&D spending to reduced external-service and personnel costs, while the decline in G&A reflected lower personnel, legal and consulting expenses.

Pipeline and regulatory developments

Phase 2 planning for izicopan in ANCA-associated vasculitis, or AAV, continued as planned. InflaRx is also planning development in atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy, with a goal of generating initial data from open-label proof-of-concept studies in 2027.

The company is evaluating several potential development approaches for AAV in the United States and Europe. This work follows the European Medicines Agency committee’s recommendation to revoke the EU marketing authorization for Tavneos, an approved C5aR inhibitor. InflaRx intends to engage with the EMA regarding both izicopan and vilobelimab, but no expedited regulatory pathway has been agreed.

InflaRx also plans to begin a pharmacokinetic bridging study for izicopan in China in late 2026. The study is intended to accelerate proof-of-concept work in additional inflammation and immunology indications.

New preclinical findings showed that izicopan did not exhibit time-dependent CYP3A4 inhibition and produced fewer reactive metabolites in human liver microsomes than avacopan. These findings support the company’s argument for a differentiated safety profile, but InflaRx cautioned that in vitro results do not directly predict clinical outcomes.

Lower operating costs were partly offset by financial-result volatility

The operating loss narrowed by approximately €5.9 million year over year, but the net loss improved by only about €3.8 million. The difference largely reflects more negative financial items below the operating line.

In Q2, other financial results shifted to a €7.9 million loss from income of €0.9 million a year earlier. This was partly offset by a €3.6 million foreign-exchange gain, compared with a €2.9 million foreign-exchange loss in Q2 2025.

For the first half, InflaRx reported a €2.0 million net financial loss versus a €3.2 million gain in the prior-year period. The company attributed the deterioration mainly to fair-value remeasurement effects associated with pre-funded warrants, partially offset by an €8.8 million improvement in foreign-exchange results.

The equity offering drove liquidity higher and expanded the share base

InflaRx sold 75 million ordinary shares at $2.00 each in May, generating net proceeds of €119.3 million, or $140.4 million. Cash and cash equivalents consequently rose to €146.6 million from €16.0 million at the end of 2025. Including €11.8 million of marketable securities, total available funds reached €158.4 million.

The increase in liquidity was primarily financing-driven. Net cash from financing activities was €119.2 million for the first six months of 2026, while operating cash use declined to €10.0 million from €21.6 million. Net cash from investing activities was €19.0 million, mainly because of proceeds from maturing marketable securities.

The offering also materially increased the share base. Q2 weighted-average shares outstanding rose to 117.7 million from 67.7 million in the prior-year quarter. Liabilities to warrant holders increased to €13.3 million from €5.8 million at the end of 2025, adding another source of potential accounting volatility.

Guidance and milestones

InflaRx’s forward outlook focused on liquidity and clinical-development timing rather than revenue or profit targets. The additional capital is expected to support several planned studies and data readouts.

Risks investors should monitor

• Clinical execution remains central: The AAV Phase 2 program and renal proof-of-concept studies are still being planned, so their timing and eventual results remain uncertain.
• The regulatory path is evolving: InflaRx is assessing possible U.S. and European pathways following the Tavneos development, but regulators have not agreed to an expedited route for izicopan or vilobelimab.
• Preclinical differentiation requires clinical confirmation: Izicopan’s CYP3A4 and reactive-metabolite findings are supportive laboratory evidence, not proof of better safety in patients.
• Losses and cash consumption continue: The company generated no quarterly revenue and used €10.0 million of operating cash during the first half. The runway through 2029 depends on future spending and development assumptions.
• Equity dilution and warrant accounting may affect per-share results: The May offering increased the share count, while warrant remeasurement can create financial-result volatility unrelated to operating expenses.

Summary

InflaRx’s Q2 2026 results showed lower operating expenses and a narrower operating loss, while warrant-related financial effects constrained the improvement in net loss. The May offering substantially strengthened liquidity and extended the projected runway through 2029, but it also increased the share base. The next operating checkpoints are progress on izicopan’s AAV development plan, the late-2026 China bridging study and initial renal proof-of-concept data targeted for 2027.